Blog

Blog Category:

Breast Cancer

2/17/2010
Ryan Newhouse
Comments (0)

Breast Cancer Drug Approved for Extended Use, says FDA

Tykerb (lapatinib) has been approved for treatment in combination with Femara (letrozole) by the U.S. Food and Drug Administration (FDA) for postmenopausal women who rely on hormonal therapy.

Tykerb targets metastatic, postmenopausal breast cancer that is HER2-positive.

Now Tykerb can be taken orally with Femara to deprive tumor cells of what they need to grow and block the function of the HER2 protein.

The approval of Tykerb was based on a study in which the Tykerb and Femara drug combination more than doubled the time women lived without the cancer progressing compared to the women who only took Femara.

Several of the side effects reported in previous Tykerb clinical studies include diarrhea, rash, fatigue, nausea, decreases in heart function, lung tissue inflammation and liver damage. It has also been reported that fetal harm may occur in pregnant women who use Tykerb to treat advanced breast cancer.

For free information about breast cancer, contact the breast cancer medical malpractice attorneys of Pittsburgh, Pennsylvania.

Bookmark and Share


There are no comments.

Post a comment

Post a Comment to "Breast Cancer Drug Approved for Extended Use, says FDA"

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."

Name:*

Email:* (will not be published)

Website:

Message:

Notify me of follow-up comments via email.

For security purposes, please enter the graphic text in the box below: [hit F5 if you can not read the text]